Investigating the effectiveness of the use of hesperidin on the clinical conditions of patients with the new coronavirus (SARS-COV-2)

Investigation of the effect of hesperidin use in patients with new coronavirus (COVID-19)

A clinical trial with a control group, with parallel, two-way blind and randomized groups on 60 patients

The present study will be a randomized clinical trial and the test population will be among the patients with new coronavirus referred to Dr. Masih Daneshvari Hospital in Tehran. All patients with admission criteria will enter the study after providing complete explanations and obtaining written consent and will enter the groups using the table of random numbers.

Inclusion Criteria: Patients with coronavirus are admitted to the new intensive care unit. Exclusion criteria: patients with intubation conditions, history of severe liver and kidney disease, patient dissatisfaction with participation in the project, age over 65 and under 18 years, history of corticosteroid therapy

In group therapy, patients receive 1 mg of hesperidin orally every 6 hours for 5 days. In the control group, patients will be under normal supervision without prescribing hesperidin. The variables are then measured over a period of time.

C-Reactive Proteine؛ Alanine aminotransferase؛ Aspartate aminotransferase؛ Bilirubine؛ lactate dehydrogenase؛ Creatinine؛ White blood cells

With simple randomization and using a random number table and individual randomization unit. To randomize, we use a table consisting of random digits 0 to 9. Each digit of this table is repeated the same on average. There is no pattern of recognizable numbers. In this method, each number is assigned to a treatment group. We start from the first line of the table and move down line by line. For the two treatments, we put the numbers 0 to 4 for treatment A and the numbers 5 to 9 for treatment B. The numbers in the first line of the table are as follows: 0,5,2,7,8,4,3,7,4,1,6,8,3,8,5,1,5,6,9,6, ... Now for people based on the above numbers, we have the following allocation: A, B, A, B, B,... We will continue the above process until the two groups are completed.

To prevent any possible complications, the primary caregiver is aware of the allocation of treatment groups. Patients in the study were also not blinded to the treatment they were receiving. Researchers responsible for data collection and analysis are not aware of the allocation of different study groups.